Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
10 9월 2024 - 7:57PM
Aclarion, Inc.,
(“Aclarion” or the “Company”) (Nasdaq: ACON,
ACONW), a healthcare technology company that is leveraging
biomarkers and proprietary augmented intelligence algorithms to
help physicians identify the location of chronic low back pain,
announced today the completion of the first Nociscan exams for
patients enrolled in the LIFEHAB Trial in Norway. The randomized
controlled trial studying 202 patients with low back pain greater
than 1 year in duration will compare treatment outcomes between
lumbar interbody fusion surgery and multidisciplinary
rehabilitation. Nociscan was selected for use in the study to help
evaluate how magnetic resonance spectroscopy (MRS) biomarkers can
identify patient improvement following treatment.
Patient enrollment in LIFEHAB began in the second quarter of
2024. The initial enrolled patients began completing Nociscan exams
in the last week of August. Thus far six (6) patients have
completed their Nociscan exams.
“We are excited to see the LIFEHAB Trial progressing on schedule
and look forward to the results of the study and to the role we
expect Nociscan data to play in not only helping physicians
determine which discs to treat but in potentially helping to
predict which treatment option is optimal for a particular
patient,” said Brent Ness, Aclarion CEO. “Although we talk
frequently about driving Nociscan to standard of care for clinical
use, the research market is proving to be an early adopter of our
technology.”
Aclarion is currently awaiting the results of a completed trial
in Rome where Nociscan technology was used in a study evaluating
regenerative technologies as well as the results of two NIH studies
evaluating the role of Nociscan in treating chronic low back
pain.
“We see Nociscan moving at an accelerated pace of adoption in
the research market and look forward to announcing more
partnerships as we continue to drive Nociscan to what we expect to
be the gold standard for determining which discs to treat in
research protocols on low back pain,” said Ryan Bond, Chief
Strategy Officer of Aclarion.
Aclarion believes the results of the LIFEHAB trial, combined
with other compelling evidence, marks a key step toward achieving
successful reimbursement in a single-payer national health
insurance system like Norway.
LIFEHAB is the latest customer-sponsored clinical trial
involving Nociscan and the Company looks forward to announcing
additional partnerships as Nociscan expands its adoption in the
research market.
For more information on the LIFEHAB Trial:
https://classic.clinicaltrials.gov/ct2/show/NCT06169488
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. For more information, please visit www.aclarion.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company’s current
expectations about future results, performance, prospects, and
opportunities. Statements that are not historical facts, such as
“anticipates,” “believes” and “expects” or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company’s current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts: Kirin M. SmithPCG Advisory,
Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024